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The Directive 2004/24/EC regarding traditional herbal
medicinal products came into force on the 30th of April
2004. The Directive will become applicable in Finland
at the same time as the reform of the Medicines Act, by
the 30th of October 2005. Traditional herbal medicinal
products are medicinal products which contain herbs
traditionally used as medicines, such as valerian, hops
or nettles. Such a product is intended for the alleviation
of small complaints and may, in addition to herbal ex-
tracts, only contain vitamins and minerals. The precon-
ditions are that the product has been used as a medicine
for at least 30 years, a minimum 15 of them within the
European Community, and that it has not been found to
cause any harm during that time.
Traditional herbal medicinal products may be sold
once they have been registered by the national authority.
Compared with the drug marketing authorisation proce-
dure, the registration system is simpler. No preclinical or
clinical trials need to be carried out with the product if
the authority considers that on the basis of experience
of use for 30 years the minor effects and safety of the
product are reliable. The quality requirements of tradi-
tional herbal medicinal products correspond to the qual-
ity requirements of conventional medicines.
EMEA already has an established committee, the
Committee for Herbal Medicinal Products, HMPC. It
started its work in the summer of 2004 with one expert
member nominated from each of the 25 member coun-
tries. The aim of the Committee is to guarantee the safe-
ty of the herbal medicinal products sold within the
Community area and to harmonise in the member coun-
tries the status of products containing medicinal herbs.
For this purpose the Committee will compile a list of
such medicinal herbal extracts and their compounds as
fulfil the requirements of the Directive and which can be
used in traditional herbal medicinal products. Within a
couple of years, these lists will form the basis for na-
tional registrations and approval for registrations.
Since 1983 the Finnish legislation on medicines has
contained regulations on products which were called
‘products similar to medicines’ at first, and now ‘herbal
medicinal products’. Marketing authorisations have
been approved for the products by the National Agency
for Medicines and their applications have been as bib-
liographic applications. Results of preclinical or clinical
trials have not been required for the products if proof
has been found in the scientific literature that the herb
contained in the product has enjoyed ‘an established sta-
tus in medical use, acknowledged efficacy and approved
level of safety’. An established status means that the
product has been used as a medicine within the EU for
at least 10 years. In other words, the marketing authori-
sation procedure for the present herbal medicinal prod-
ucts has already been a kind of less onerous version of
the proper procedure.
While reform of the Medicines Act is taking place, a
few of the present herbal medicinal products will be
considered as traditional herbal medicinal products re-
ferred to in the new Act, for example, certain products
containing ginseng. Some of the herbal medicinal prod-
ucts do not, however, fulfil the definition of a tradition-
al herbal medicinal product, and consequently a number
of products may also fall into the category of conven-
tional medicinal products. Following the reform of the
Medicines Act, depending on the composition, tradition-
al use and therapeutic indications, a herbal medicinal
product may be a subject either for registration as a tra-
ditional herbal medicinal product or for a marketing au-
thorisation application as a conventional medicinal
product.
Traditional herbal medicinal products – 
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Asymptomatic growth of bacteria
(bacteriuria) is a very common find-
ing in the elderly population. Its
prevalence increases with age as it is
found in 20% of women aged 80
and over and in 10% of men in the
corresponding age group. The risk
of bacteriuria is also increased by re-
duced functional ability.
Bacterial colonisation in the peri-
urethral area is of key importance in
the development of bacteriuria. Bac-
terial colonisation is increased by
oestrogen deficiency, a lack of bacte-
ricidal prostate secretions and faecal
incontinence. Even though oestrogen
deficiency is considered a risk factor
for bacterial colonisation, oestrogen
therapy has not been found to de-
crease the occurrence of bacteriuria
in women in institutionalised care.
Asymptomatic bacteriuria is found
in 15–30% of men in institution-
alised care, whereas the correspon-
ding percentage in women is 30–50.
Bacteria are detected in the urine of
all patients with a permanent
catheter in place for a minimum of
two weeks (1, 2). 
According to the literature, the
frequency of symptomatic urinary
tract infection is 0.1–2.4 per 1,000
days of treatment. The big differ-
ences between various studies are
explained by the number of patient
specific risk factors and the criteria
used in the diagnosis of the infec-
tion. Symptomatic infections are
more common in women, in whom
the frequency is about four times
that in men. Urinary tract infection
with fever is nevertheless distinctly
rarer and its frequency in different
studies has varied between 0.05 and
0.10 per 1,000 days of treatment.
Factors exposing the patient to
urinary tract infection include for-
eign objects in the urinary tract, e.g.
catheters, and difficulty in emptying
the bladder. Bladder emptying diffi-
culties are usually due to prostate
hyperplasia, uterine prolapse or neu-
rogenic disorders of the bladder (1,
2).
Diagnosis of urinary tract in-
fection – a general approach
Asymptomatic bacteriuria in institu-
tionalised patients should not be
treated with antimicrobials except
prior to elective urological proce-
dures. According to three random-
ised, prospective studies, such treat-
ment of asymptomatic bacteriuria
did not reduce the prevalence of
symptomatic infections or the mor-
tality in institutionalised patients (3,
4) or the elderly (5). The unneces-
sary use of antimicrobials increases
the costs and exposes the patients
unnecessarily to adverse effects. Un-
necessary use of antimicrobials
should also be avoided because it in-
creases the antimicrobial resistance.
Several studies on long-term-care fa-
cilities have shown that preceding
antimicrobial medication is a risk
factor for the resistant microbial
colonisation or consequent infection.
It is difficult to spot the possibility
of resistance in empirical treatment,
and consequently the outcome of
treatment for severe infections in
carriers of resistant microbes may be
poorer than in other patients. In
long-term-care facilities, resistant
microbes may be transmitted from
patient to patient by contact infec-
tion. Copious use of antimicrobials
promotes the selection of resistant
microbes, which may easily result in
an endemic of these organisms. In
the hospital district of Helsinki and
Uusimaa, the majority of the strains
isolated from the urine in long-term-
care departments are E. coli strains
resistant to third generation cephal-
osporins (ESBL producing strains).
Since treatment of asymptomatic
bacterial growth with antimicrobials
is common in institutionalised pa-
tients, attempts have been made to
create various combinations of defi-
nitions for the diagnosis of sympto-
matic urinary tract infection. The
minimum criteria set at a US con-
sensus meeting for urinary tract in-
fections in cases where the institu-
tionalised patient does not have a
foreign object in the urinary tract
are presented in Table 1. (6)  If the
Urinary tract infections in elderly institutionalised
patients
ELINA KOLHO
MD, Specialist in Internal Medicine
HUS
Urinary tract infection is the
most common bacterial
infection in patients in long-
term-care facilities. A prevalence
study carried out in the USA
showed that almost one in ten
institutionalised patients had
been prescribed a systemic
antimicrobial. As many as half
of these medications are indicat-
ed as having been for the treat-
ment of urinary infections.
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patient does not have a urinary tract
catheter in place, the diagnosis of
urinary tract infection according to
these criteria always requires symp-
toms localised in the urinary tract,
with an acute onset or acute exacer-
bation (6). If the patient has a uri-
nary tract catheter in place, the
symptoms of lower urinary tract in-
fections are absent. The indication
for therapy is a suspected upper uri-
nary tract infection, the symptoms
of which either in combination or
alone include fever, fits of shivering,
delirium or hypotension (6).
Unspecific symptoms in institu-
tionalised patients, e.g. loss of ap-
petite, tiredness, nausea and confu-
sion are often suspected of resulting
from a urinary tract infection. Gen-
eral symptoms are nevertheless sel-
dom the result of a urinary tract in-
fection. In practice, diagnosing and
deciding on the correct treatment
may be difficult, especially if the pa-
tient is suffering from numerous
cognitive disorders, which makes it
difficult to obtain from him/her a re-
liable history of urinary tract symp-
toms. If, due to unspecific symp-
toms, treatment of bacteriuria is in-
dicated as the outcome of diagnosis,
the symptomatic picture should be
recorded prior to treatment, fol-
lowed by a record of the response.
This will help in the choice of treat-
ment in future.
A Canadian survey looked into
why treatment is so frequently given
for asymptomatic bacteriuria. The
survey comprised 16 nurses and 17
doctors with over five years’ experi-
ence of working in long-term-care
facilities. Urine culture was often
done at the instigation of a nurse
and on account of non-specific
symptoms. The indications described
by the nurses were, e.g.: “the patient
was not quite right” or “the culture
was done just in case”. The doctors
had started the treatment on the ba-
sis of urinary findings, because they
were not actually in charge of the
care and they believed that the cul-
tures were done owing to symptoms,
or they were uncertain about the in-
terpretation of the urinary findings,
or they were afraid that the asymp-
tomatic bacteriuria would result in a
severe infection (7).
Diagnosis based on laboratory
findings
The diagnosis of a urinary tract
infection is made not only on the
basis of symptoms exhibited but al-
so on the basis of significant bacteri-
al growth found in the urine. New
recommendations have recently been
issued on the limits of significant
growth. The new recommendations
give different limit values to each
type of infection (Table 2). These
limit values have not been validated
in long-term-care facility residents,
in whom the limit of significant bac-
terial growth could still, as a rule, be
considered to be 105 bacteria/ml (2).
If the symptoms of a urinary tract
infection exhibited by a long-term-
care facility resident are unambigu-
ous, the diagnosis of a urinary tract
infection may nevertheless be con-
sidered confirmed even with a lower
number of bacteria.
A urinary culture is an important
method of examination when a uri-
nary tract infection is suspected in a
long-term-care facility resident, since
the range of factors likely to cause
infection is wider than that in out-
patient care (Table 3). A urinary cul-
ture confirms the correct choice of
medication. A urinary bacterial cul-
ture makes it also possible to moni-
tor the prevalence and pathogenesis
of urinary tract infections in the care
facility or department. Monitoring
Table 1. Minimum criteria of urinary tract infections according to a US consen-
sus meeting (6)
Dysuria, or
axillary temperature  > 37.8° and at least one of the following:
Increased compulsion to micturate; either a new symptom or in
creased from previously
Increased desire to micturate; either a new symptom or increased 
from previously
Suprapubic pain
Hypersensitivity in the renal region 
Macroscopic haematuria
New urinary incontinence
Table 2. Limit values of urinary culture in different types of infection
Uncomplicated urinary tract infection in women 102 bacteria/ml 
(pyuria is expected)*
Complicated urinary tract infection in women 105 bacteria/ml
Lower urinary tract infection in men 104 bacteria/ml 
(pyuria is expected)
Pyelonephritis 104 bacteria/ml 
(pyuria is expected)
* the sensitivity level of a common urinary culture is 103 bacteria/ml
Table 3. Inducers of urinary tract
infections in long-term-care resi-
dents
Gram-negative rods
E. coli
Klebsiella species
Proteus species
Enterobacter species 
Providencia stuartii
Morganella morganii
Serratie marcencens
Citrobacter freundii
Pseudomonas aeruginosa
Gram-positive cocci
Enterococci species
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will also reveal any epidemics of in-
fection and any resistance problems
present.
The urine sample is usually taken
from a midstream urine. It is unclear
whether washing of the periurethral
area reduces the bacterial contami-
nation significantly. Catheterisation
on a single occasion only to obtain a
urine sample in women is justified if
it proves impossible to take the urine
sample in any other way. If the pa-
tient becomes symptom-free with an-
timicrobial therapy, monitoring of
the urinary culture is not necessary
following the treatment (1, 2, 8).
Other urinary examinations in
long-term-care patients are less bene-
ficial. Absence of leukocytes in the
urinary sample usually excludes any
significant bacterial growth reliably
enough, unless the patient is neu-
tropenic. Even if the number of
leukocytes present in the blood is
greater than normal, the finding
does not necessarily portend signifi-
cant bacteriuria, because as many as
a third of long-term-care residents
are found to have pyuria without
significant bacterial growth. Asymp-
tomatic bacteriuria also produces an
inflammatory response in the urinary
tract, which is why 90% of patients
with asymptomatic bacteriuria also
have pyuria (1, 2, 8). A number of
leukocytes in the urinary sediment of
more than 10 leukocytes in the field
of vision is significant; less than 5
leukocytes is a normal finding
whereas 5–10 leukocytes are found
in indeterminate instances.
Examination of the urinary sedi-
ment is laborious, and consequently,
most places use a strip test for
screening. A strip test assesses the
leukocyte esterase to detect pyuria
and the nitrite test is used as chemi-
cal marker for bacteriuria. The sensi-
tivity and specificity of a strip test to
detect pyuria (over 10 leukocytes in
the field of vision) are relatively
good; the sensitivity is 75–96% and
the specificity is 94–98%. The speci-
ficity of the nitrite test is good, but
its sensitivity to detect a significant
bacteriuria is below 30% and in
long-term-care residents it is likely to
be even poorer. In theory, the nitrite
test is positive if the urine contains a
significant number of bacteria,
which produce nitrite, provided that
a sufficient amount of nitrates are
obtained from food. All the patho-
gens, such as enterococci and Pseu-
do-monas aeruginosa, which are the
common causes of urinary tract in-
fections in long-term-care residents,
do not, however, produce nitrite. A
nitrite test not positive either unless
the urine has stayed in the bladder
for at least four hours, because a
shorter time is not long enough for
the bacteria to transform nitrate into
nitrite.
Classification and treatment of
lower urinary tract infections
Urinary tract infections are classified
as uncomplicated or complicated. A
urinary tract infection is complicated
if the patient suffers from obstruc-
tive uropathy or a bladder retention
amounting to over 50 ml. A urinary
tract infection is also classified as
complicated if the patient suffers
from renal impairment, because the
secretion of antimicrobials in the
urine may be reduced. The division
is important, because uncomplicated
urinary tract infections can be treat-
ed with a 3–5 day course of antimi-
crobials, depending on the drug,
whereas a complicated infection re-
quires a course of treatment lasting
for 7–14 days, rarely even longer.
Occasionally, a complicated urinary
tract infection will not clear up, and
the only way out is a long suppres-
sive therapy. Normal therapeutic
doses for urinary tract infections, in-
stead of prophylactic doses, are ap-
plied in such treatment. The urinary
culture is monitored at one month
intervals during treatment to ensure
that resistance is not developing to
the drug used, and that other strains
which would be resistant to the drug
used will not be selected.
A relapse of a urinary tract infec-
tion implies that a symptomatic in-
fection caused by the same microbe
is found two weeks after the comple-
tion of the antimicrobial therapy.
The usual cause of relapse is an inef-
fective antimicrobial therapy or an
insufficiently long course of treat-
ment. Reasons for antimicrobial
therapies being too short include, for
example, that the patient’s infection
has been a complicated one after all,
or that the patient suffers from a
bacterial prostatitis. It might also
have been an upper urinary tract in-
fection with a short course of drug
therapy or with insufficient concen-
trations of the chosen drug in the re-
nal tissue. An infection fulfilling the
criteria of a relapse may of course
sometimes, in reality, be a re-infec-
tion. A suspected relapse always re-
quires to be somewhat more closely
examined.
It is hoped that the choice of an
antimicrobial will be made easier by
a Finnish Current Care Recommen-
dation which is being updated at the
moment. In the choice of medical
treatment for long-term-care resi-
dents the general guidelines are only
indicative, since the choice should
take into consideration the patho-
gens responsible for the patient’s
previous infections, the history of
antimicrobials used so far, and the
endemic microbes of the institution
or the department and their situation
with regard to sensitivity.
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In reporting of adverse drug reac-
tions another record was made last
year, a total of 1,118 reports having
been received. Almost half of the re-
ports were of serious reactions, i.e.
ones which either resulted in or pro-
longed hospitalisation, caused a per-
manent injury or reduced the func-
tional ability, or were life-threaten-
ing or fatal.
Conclusions about differences
among the drugs cannot be made di-
rectly on the basis of the number of
reactions they caused: frequent use
will generally generate a higher
number of adverse reactions and a
greater number of reports are re-
ceived on new drugs – which is the
way it should be. There are usually
more frequent reports on drugs fig-
uring in the media headlines, and
the zeal with which the pharmaceu-
tical companies themselves record
the reactions they have been made
aware of may perhaps manifest itself
in the increased numbers of reports
of adverse drug reactions.
Cholesterol-lowering drugs
The largest number of reports of ad-
verse drug reactions this year were
made about rosuvastatin (by the
trade name Crestor); a total of 38
reports. About half of these were of
myalgia or a combination of myal-
gia and elevated creatine kinase.
There were also reports of elevated
liver values. The sales of rosuvas-
tatin were equal to those of fluvas-
tatin (Lescol), which was the subject
of 9 reports, but fluvastatin was in-
troduced on to the market year
1996, whereas rosuvastatin was on-
ly introduced year 2003. Six reports
of adverse reactions of fluvastatin
were of liver effects.
Atorvastatin (Lipitor), which was
the drug mostly used in this group,
was reported 18 times as having
been associated with various symp-
toms, among which pancreatitis is
the one that figures most prominent-
ly (4 reports). Simvastatin was re-
ported 15 times regarding the vari-
ety of adverse reactions it caused,
mostly elevated liver values or myal-
gia. 
Anti-inflammatory and anti-
rheumatic agents
The second highest number of re-
ports of adverse reactions received
concerned valdecoxib (Bextra); 31
reports in total. They do not focus
directly on any one particular reac-
tion: haematoma, liver reactions and
urticaria were each reported 4 times,
and, at a quick glance anyway, the
rest of the reactions appear to be
sporadic.
Etoricoxib, or Arcoxia, was re-
ported to NAM on 26 occasions.
Five of them were about elevated
liver values, 3 about oedema of the
feet and 2 about facial oedema.
Celecoxib (Celebra) appears 20
times in last year’s records; three of
the cases concerning an allergic reac-
tion, two anaphylaxis and five some
form of skin reaction.
Fourteen reports were received
on rofecoxib (Vioxx, Vioxxakut)
with no specific emphasis on any
single effect. Only a couple of ad-
verse cardiac reactions were men-
tioned in the coxib group, even
though there was an outcry about
these reactions in other countries.
However, the reports on coxibs in-
clude four cases of ulcer.
The coxibs were introduced on
to the market relatively concomi-
tantly followed by insignificant dif-
ferences in their sales figures and the
number of adverse reactions report-
ed. The majority of the reports were
about valdecoxib, which was also
the drug mostly sold. It is not possi-
ble to draw any important conclu-
sions about these adverse effects.
Only occasional reports were re-
ceived concerning conventional anti-
inflammatory analgesics.
As in previous years, the majori-
ty of the reports in the antirheumat-
ics group were about infliximab
(Remicade); a total of 16 reports.
Etanercept (Enbrel) and leflunomide
(Arava) were each reported 12
times, and adalimumab (Humira) 8
times. There does not seem to a spe-
cial focus on any individual drug
TAPANI VUOLA
Senior Medical Officer
LEENA SOMMARBERG
Researcher
TINNA VOIPIO
Researcher
National Agency for Medicines
Reports received by the Adverse Drug Reaction
register in 2004
In English
Adverse Drug Reactions
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this time, except for the five cases of
skin rash reported in association
with the use of etanercept. The en-
tire group contains 7 reports of
blood count changes, 4 of vasculitis
and 3 of pulmonary fibrosis.
Antimicrobials
The third highest number of reports
last year were about levofloxacin
(Tavanic), which took the first place
in the list the previous year. Except
in a couple of instances, the reports
were about the typical effect of the
drug, i.e. inflammation and/or rup-
ture of the Achilles tendon. A col-
league, Marja-Leena Nurminen, re-
viewed the situation in the article on
ADRs in 2003 (TABU 2/2004): el-
derly men (76%) on concomitant
corticosteroid therapy appear to be
especially predisposed to this reac-
tion. This can also indicate that the
drug is used with careful considera-
tion in severe cases. Individual cases
have also occurred without con-
comitant medication with cortico-
steroids, and consequently, whenev-
er tendinitis is suspected, the use of
the drug should be stopped immedi-
ately. A couple of reports of adverse
effects on the Achilles tendon were
also received in association with the
use of moxifloxacin (Avelox) and
ciprofloxacin (several products).
Telithromycin (Ketek) was re-
ported 14 times last year. Three of
the reports concerned visual distur-
bances, the rest being various. The
combination product of nitrofuran-
toin and ascorbic acid was also re-
ported 14 times. Half of these con-
cerned the well-known adverse pul-
monary effects of nitrofurantoin,
pulmonary infiltration or pulmonary
fibrosis. 
Terbinafine (Lamisil) indicated
for the treatment of fungal infec-
tions was the cause of 15 reports,
half of which were about either the
lack of or disturbance of the sense
of taste, which is a well-known ad-
verse effect of the drug. Only spo-
radic reports were received on the
rest of the antimicrobials.
Hormones
The fourth position on the list of ad-
verse reactions last year has a con-
traceptive ring (NuvaRing) which
contains etonogestrel and ethinyl-
estradiol. It was reported 26 times,
and except for the six reports that
were about various reactions, as
many as 20 concerned the problem
of unintended pregnancy. 
In proportion with the sales fig-
ures, a contraceptive patch (Evra)
containing ethinylestradiol and
norelgestromine caused about the
same number of reports of adverse
reactions, i.e. nine, eight out of
which were cases of unintended
pregnancy. Contraceptive pills (Yas-
min) containing ethinylestradiol and
drospirenone were the object of re-
porting 8 times. Two of these re-
ports concerned pulmonary embol-
ism, two others were about cerebral
embolism and cerebral infarction.
The use of all hormonal contracep-
tive products is associated with in-
creased risk of venous and arterial
thrombosis. It is not known at pre-
sent, how high the risk is with these
more recent products in comparison
with the older ones.
Tibolone appears among other
hormone products; it was reported
10 times, 5 of the cases were of en-
dometrial cancer, one of breast can-
cer and one of ovarian cancer. Eval-
uation of these cases is nevertheless
difficult; the likelihood of cancer
grows with age, and before tibolone
was introduced for the treatment of
menopausal complaints, all the
women except for one had for years
used other hormone therapies. Con-
sequently, the summaries of product
characteristics of all products of this
group include very comprehensive
warnings.
Antipsychotics, antidepres-
sants and bupropione
The fourth and fifth positions on the
list are held by clozapine and bupro-
pione, respectively. A total of 26 re-
ports were about clozapine, 17 of
which were about its already long
and well known adverse effects on
blood. Among the antipsychotics in
this list, quetiapine (Seroquel) fig-
ured 14 times. A variety of reactions
were reported, but those most typi-
cal of antipsychotics included: three
cases of malignant neuroleptic syn-
”TOP 20” LIST   
Medicines Number of  
ADR reports
rosuvastatin 38  
valdecoxib 31  
levofloxacin 28  
clozapine 26  
vaginal ring with etonogestrel 
and ethinylestradiol 26  
etoricoxib 26  
bupropione 25  
celecoxib 20  
atorvastatin 18  
iomeprol 18  
infliximab 16  
simvastatin 15   
terbinafine 15  
venlafaxine 15  
quetiapine 14  
lamotrigin  14  
mirtazapine 14  
combination preparation with 
nitrofurantoin and ascorbic acid 14  
rofecoxib 14  
telithromycin 14  
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drome, 2 of granulocytopenia, one
of dystonia and one of tardive dys-
kinesia, plus a variety of other indi-
vidual cases, such as hyperglycemia,
prolongation of QT-interval and he-
patitis. Olanzapine (Zyprexa) and
risperidone were reported 7 times,
including various adverse reactions
typical for antipsychotics.
Bupropione (Zyban), used to
help people to stop smoking, was re-
ported 25 times. The majority of the
cases were associated with various
mental reactions (7 in all), but ur-
ticaria (4) and skin reactions (4)
were also reported.
Among antidepressants there are
15 adverse drug reaction reports
about venlafaxine (Efexor) and 14
reports about mirtazapine. In the
case of venlafaxine, attention is
drawn to QT-interval prolongation,
which was the reason for reporting
on four occasions. In the case of
mirtazapine the focus is on the 7 re-
ports of epileptic seizures. The ad-
verse reactions are mentioned in the
summaries of product characteristics
of both.
Among the more recent antide-
pressants, escitalopram (Cipralex)
received 9 reports, focusing on a va-
riety of reactions. Milnacipran (Ixel)
was reported 7 times, four of which
were about hypertension.
Contrast media
‘Lasting favourites’, as it were,
among reportees appear to be the
commonly used iomeprol, iopromide
and iohexol, which were reported
on 18, 13 and 11 occasions, respec-
tively. These iodine-containing con-
trast media do not appear to differ
from one another in respect of their
adverse effects. The most commonly
reported reactions in this group in-
cluded urticaria, allergic reaction,
nausea and anaphylactic reaction.
Individual medicines
Some individual drugs appeared on
the list of the most commonly re-
ported drugs: an antiepileptic agent,
lamotrigine (Lamictal) was reported
14 times, half of which concerned
cases of various skin reactions of
which there also are warnings in its
summary of product characteristics.
An anticancer drug, capecitabine
(Xeloda) was mentioned 11 times,
four cases of which referred to a
cardiac adverse reaction. Candesar-
tane was a drug under suspicion a
total of 10 times in the list of re-
ports. There does not appear to be
any particular trend in these reports.
Reporting of adverse drug 
reactions 
The reports play an important role
in the evaluation of safety profiles,
especially those of the more recent
drugs. Prior to introduction on to
the market, a drug has always un-
dergone testing with a small group
of patients who are usually very
carefully selected. It is not until
large numbers of patients have been
exposed to a drug that its real safety
in use can be established. Conse-
quently, special interest at NAM is
focused on new types of adverse re-
actions, new drugs, adverse reac-
tions exhibited in new patient
groups and any changes occurring in
the frequency of the reactions. It
would also be useful if interactions
with new drugs were reported.
To make reporting easier, we
have released a form in Finnish,
which is available for filling in and
forwarding on the Internet. It can be
found at: http://hava.nam.fi (please
note: no www-prefix). 
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Small sterilizers in Finnish health care
In English
The method of steam sterilization is
to be preferred to hot air steriliza-
tion. A European standard (SFS-EN
13060:2004) defines small sterilizers
as steam sterilizers with a chamber
capacity not exceeding 60 litres. It is
customary to classify the small auto-
claves according to the programmes
they use (Table 1).
A large number of small steriliz-
ers in use do not yet fulfil the re-
quirements of the standard SFS-EN
13060. Old autoclaves do not have
a pre-vacuum phase, and their pro-
grammes are therefore similar to the
type N programmes referred to in
the standard for small steam steriliz-
ers. For the purposes of this article,
type N autoclaves fulfilling the re-
quirements of the standard and old
autoclaves have both been dealed
here as ‘type N autoclaves’. Cassette
autoclaves of the type used in den-
tistry do not have a pre-vacuum
phase either. They are primarily used
for sterilization of instruments.
Purpose of the study
The Finnish Agency for Medicines
carried out a project in 2003–-2004
with the purpose of mapping out the
existing selection of small autoclaves
in primary care in Finland and de-
tails of their use. Initial details of a
total of 1,003 small autoclaves were
received from the biggest suppliers
of equipment before the actual start
of the study. The majority of devices
sold in recent years comply with the
standard SFS-EN 13060 on small
steam sterilizers.
The survey comprised 272 health
care centres or municipal health cen-
tres and 1,090 private doctor’s surg-
eries. The health care centres also
included units with exclusively den-
tal care services. 
The outcome
The survey questionnaire was com-
pleted by 90% of the care units. In-
formation was gathered about 1,519
sterilizers from 730 care units. 86%
of the health care centres  and 45%
of the private care units had a steril-
izer. A couple of units reported of
having outsourced their sterilization
operations. Small sterilizers used
solely in dental care numbered 182
(12%).
The majority, i.e. almost a third,
of the devices were hot air sterilizers
(Fig 1). Among table top autoclaves,
the proportion of type B autoclaves
(with pulsating pre-vacuum) and
type N autoclaves was equal, about
22%.
The average age of the devices
was about 12 years, but the age dis-
tribution was conspicuously wide
(Fig 2). The oldest hot air chamber
had been in use for 48 years. The
average age of hot air chambers was
17 years, and that of small auto-
claves 10 years. The number of
small sterilizers older than 20 years
was 231, 133 of which were hot air
chambers and 76 small autoclaves.
The sterilizers were mainly used
to sterilize instruments. 106 steriliz-
Table 1. Small sterilizers
• The type B autoclave is appropriate for all types of sterilization. Expulsion of
air from the autoclave is done through fractionated pre-vacuum phases after
which the chamber is filled with saturated steam. Type B autoclaves are also
appropriate for sterilization of textiles.
• The type N autoclave is only appropriate for sterilization of unwrapped solid
items. This type of autoclave does not contain a vacuum pump. The sterilized
items may not be wrapped, and the items must be used immediately after
sterilization. These autoclaves must not be used for sterilization of textiles or
hollow or tubular devices, because any residue air can jeopardize the
success of sterilization.
• The type S autoclave incorporates a number of special programmes for the
sterilization of hollow, porous or wrapped devices. These autoclaves can be
used to sterilise wrapped items, textiles or tubular items only if the autoclave
contains an appropriate programme for doing so.
The purpose of sterilization of
medical devices is to prevent
infection through contamin-
ation. In primary health care
sterilization is usually done
using small sterilization equip-
ment: hot air chambers or small
steam autoclaves. The responsi-
bility for the sterilization proce-
dure and associated supervision
lies with a competent user. By
law, a professional user is an
operative unit within social wel-
fare and health care.
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ers were used to sterilize textiles de-
spite the fact that they did not incor-
porate a pre-vacuum phase.
Wrapped instruments were also in-
correctly sterilized in 269 autoclaves
without a pre-vacuum phase, and in
68 cassette autoclaves.
Variations including actual defi-
ciencies were also found in the mon-
itoring of the sterilizing efficiency of
the sterilizers. A process indicator,
an autoclave colour tape, for exam-
ple, should be included in every run,
but this was only included in 70%
of the runs. An autoclave tape glued
on to the items was often the only
indicator used; this would not give
an indication of a successful steril-
ization process, but instead only of
the fact that the item has been in an
autoclave. An autoclave leak detec-
tion test was carried out at least
once a week in only about 12%,
and a Bowie & Dick test to measure
the air expulsion capacity only in
9%, of the type B table top auto-
claves. Nearly 10% of the survey
participants reported that they car-
ried out this test on type N auto-
claves, despite the fact that the test
cannot be carried out on this type of
autoclave.
Figure 1. Types of sterilizers 
Figure 2. Age of sterilizers 
The status of hot air sterilizers
was equally poor: the temperature,
time and pressure were monitored in
about 42% of the runs and an auto-
clave colour tape was used in about
every other sterilization run. Only
about 7% of the thermometers were
calibrated as recommended, i.e. at
least once a year. 48% of the ther-
mometers had never been calibrated.
Biological indicators were used at
least every 6 months in only about
12% of the equipment.
A total of 182 (13%) of the
small sterilizers had no monitoring
of efficiency at all (no autoclave
colour tapes, biological indicators,
leak detection tests, Bowie & Dick
tests or calibration of equipment
were used) (Table 2). Hot air steril-
izers were found to have the rela-
tively poorest monitoring status: 96
(22%) of them were not monitored
at all. 
The frequency of maintenance of
the equipment varied greatly. Steril-
izers underwent maintenance after
between 40 and 2,500 uses. Some
equipment had never undergone
maintenance, even though they had
been bought as long ago as in the
1970’s.
Conclusions
Finland lacks a comprehensive data-
base of small sterilizers. The survey
revealed that the selection of equip-
ment in use is often considerably
old. Sterilizers older than 20–25
years are no longer necessarily reli-
able and require more service and
maintenance to work as properly as
new sterilizers which comply with
the standard for small steam steriliz-
ers. The use of small sterilizers older
than 20 years should actually be to-
tally abandoned. The alternatives
consist of introducing single use
products or buying sterilizing ser-
vices from an external equipment
service.
The new type B autoclaves,
which comply with the standard for
small steam sterilizers and which
can be used for sterilization of
wrapped items and textiles, were
found in about 23% of the units of
the survey. They will gradually re-
place the old autoclaves in which
the residual air is not removed by
vacuum.
There are still small autoclaves in
Finland in which the residual air is
not removed by a pre-vacuum
phase. There is usually no system of
pre-removal of residual air in the
cassette autoclaves either. However,
81% of those taking part in the sur-
vey reported that they sterilized
wrapped devices and items with
these autoclaves as well.
There are big deficiencies in the
monitoring of the sterilization
processes. The temperature, time
and pressure are monitored in only
less than 50% of the sterilization
processes. The biggest cause for con-
cern arises from the fact that the
sterilization process in about 13%
of all small sterilizers is not moni-
tored in any way at all. This shows
the lack of knowledge about the
sterilization process and associated
responsibilities in those people an-
swerable for the sterilization.
The Act on Medical Devices in-
cludes general requirements with re-
spect to competent professional use
and obligations regarding quality as-
surance and the safeguarding of reli-
able operation. A competent profes-
sional user, in this case a health care
unit, is answerable for the safety
and use of the medical device. The
use of old autoclaves includes risks
of unsuccessful sterilizations, possi-
ble infections and risks involved
with the use of pressure vessels. The
quality assurance systems of health
care operational units require the
use of sterilizers which comply with
the standard mentioned earlier, or
the introduction of disposable prod-
ucts.
Proposals for future measures
The use of sterilizers older than 20
years is not recommended, because
guaranteeing their sterilizing capaci-
ty is a complex matter. The mea-
sures for servicing old equipment be-
come costly, and this applies also to
the organisation and maintenance of
staff training. The time spent on ser-
vicing the equipment could often be
better spent on other duties.
The survey revealed the need for
training and information among the
staff of the equipment service. Train-
ing should be arranged regionally,
for example, in association with
each hospital district’s own training.
Measures need to be taken to re-
dress the apparent deficiencies de-
tected in the monitoring of small
sterilizing equipment and the need
for training among the users.
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Table 2. Small sterilizers with total lack of monitoring*)  
Type of sterilizer % number
Hot air sterilizer 22,3 96
Type N autoclave 12,0 40
Type S autoclave 11,5 24
Cassette autoclave 7,5 8
Type B autoclave 4,1 14
Total 182
*) no process or biological indicators, no sterilizer leak testing, no Bowie Dick test or
equipment calibration carried out 
